Detalles de la búsqueda
1.
The efficacy and safety of pemetrexed plus bevacizumab in previously treated patients with advanced non-squamous non-small cell lung cancer (ns-NSCLC).
Tumour Biol
; 36(4): 2491-9, 2015 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-25417899
2.
IDO1/COX2 Expression Is Associated with Poor Prognosis in Colorectal Cancer Liver Oligometastases.
J Pers Med
; 13(3)2023 Mar 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-36983678
3.
The Pan-Immune-Inflammation Value predicts the survival of patients with anaplastic lymphoma kinase-positive non-small cell lung cancer treated with first-line ALK inhibitor.
Transl Oncol
; 17: 101338, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-34999541
4.
Clinical benefit of continuing crizotinib therapy after initial disease progression in Chinese patients with advanced ALK-rearranged non-small-cell lung cancer.
Oncotarget
; 8(25): 41631-41640, 2017 Jun 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-28427213
5.
Continuation of epidermal growth factor receptor tyrosine kinase inhibitor treatment prolongs disease control in non-small-cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors.
Oncotarget
; 6(28): 24904-11, 2015 Sep 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-26172562
Resultados
1 -
5
de 5
1
Próxima >
>>